This Series C round supports Nscale’s acceleration of AI infrastructure deployments globally, valuing Nscale at $14.6 billion

Sheryl Sandberg, Susan Decker, and Nick Clegg join Nscale’s Board of Directors

LONDON, March 9, 2026 — U.K.- based AI infrastructure hyperscaler Nscale today announced its $2 billion in Series C funding, led by Aker ASA and 8090 Industries. This round values Nscale at $14.6 billion. The funding round was supported by Astra Capital Management, Citadel, Dell, Jane Street, Lenovo, Linden Advisors, Nokia, NVIDIA, and Point72. This new raise will further accelerate Nscale’s global development of vertically integrated AI infrastructure — from GPU compute and networking to data services and orchestration software — across Europe, North America, and Asia.

AI is reshaping industries, economies and national strategies, and accelerated computing platforms are the engine driving that shift. The constraint on market scaling is not demand, but the ability to deploy capacity and run it reliably in production. Nscale is purpose-built to accelerate AI deployments. This capital deepens Nscale’s infrastructure footprint, expands its engineering and operations teams, and strengthens the platform, enabling Nscale to continue to deliver real, production-grade AI deployments at massive scale.

“This is the fourth industrial revolution; the world is changing at a rapid pace. Over the next 5 years, Artificial Intelligence will be integrated into every industry, every product, and every job. Accelerating drug discovery, extending human life, autonomizing travel and robotics, lifting productivity, and driving massive growth. This is leading to the largest infrastructure buildout in human history,” said Josh Payne, CEO and Founder of Nscale. “Nscale is leading this buildout. We are building this foundation that the market sits on, the engine of superintelligence.”

Strengthening Nscale’s Board

Nscale also today welcomes three new Directors. Sheryl Sandberg, Susan Decker, and Nick Clegg will join the Nscale Board, bringing substantial global depth across technology, policy, operations, and governance to an already world-class collection of business leaders.

Sheryl Sandberg — Sandberg is currently the co-founder of Sandberg Bernthal Venture Partners, which deploys private capital to fund innovation across consumer, enterprise, climate and healthcare technology. As former Chief Operating Officer of Meta and an early executive at Google, Sandberg brings unmatched experience in scaling the world’s most influential technology companies, as well as deep expertise in operations, growth strategy, and building global organizations.

Susan Decker — Decker is the CEO and co-founder of Raftr, a Community Experience platform for universities. She is a former President of Yahoo, Inc. and is currently a Board member at Costco Wholesale Corporation, Berkshire Hathaway, Vail Resorts, Chime, Vox Media, and Automattic. Decker brings sharp financial acumen, governance expertise, and strategic leadership developed across decades at the forefront of global media and technology companies.

Nick Clegg — A current General Partner at Hiro Capital, Clegg focuses on fostering the growth of leading spatial computing technologies within Europe. He is both a former UK Deputy Prime Minister and former President, Global Affairs at Meta. Prior to being elected to the UK Parliament in 2005, Clegg served five years in the European Parliament. Clegg brings deep expertise at the intersection of technology, policy, and global affairs and has most recently been at the center of the most consequential regulatory and governance conversations shaping the future of AI.

Sandberg, Decker, and Clegg join Nscale’s existing Board of Directors, which includes Josh Payne, Rael Nurick, Jacob Leschly, and Øyvind Eriksen.

Streamlining Execution in Norway

Alongside this Series C funding and its new Directors, Nscale has reached an agreement with Aker to roll the Aker Nscale joint venture — announced in July 2025 — fully into Nscale. Going forward, Aker will remain a leading shareholder in Nscale with its CEO Øyvind Eriksen continuing to serve on the Nscale Board.

This decision consolidates delivery and governance under one entity, while ensuring all existing projects under the joint venture continue and remain fully operational as part of Nscale. This ongoing partnership has been foundational to Nscale’s growth and demonstrates its continued commitment to playing a positive, long-term role in the communities where it operates. Nscale’s firm pledge to waste heat reuse, local skills development, and investment in regional infrastructure remains unchanged.

Øyvind Eriksen, President and CEO of Aker ASA said, “This step strengthens execution by putting delivery and governance under one roof, while keeping continuity for the people and projects already underway. We have full confidence in Nscale’s ability to deliver responsibly in Norway over the long term, and we believe this positions the work for faster progress and durable value creation.”

Rayyan Islam, the Co-founder and General Partner of 8090 Industries said, “We are living through a new era defined by AI, and the limiting factor is infrastructure. Compute, energy, and industrial-scale deployment capacity will determine which nations and companies lead the next generation of technological and economic progress.

Nscale has built a platform uniquely capable of solving this challenge by vertically integrating the critical layers of AI infrastructure — from energy and data centers to compute and orchestration.

At 8090 Industries, we invest in the systems that enable entire industries to scale and are proud to partner with Josh and the Nscale team as they build the foundational backbone for the global AI economy.”

Goldman Sachs & Co. LLC and J.P. Morgan acted as joint placement agents for Nscale in connection with this capital raise which is inclusive of the Pre-Series C SAFE.

About Nscale

Nscale is the global hyperscaler engineered for AI infrastructure. Through vertically integrated AI solutions and modular, first-principles data center design across Europe, North America, and beyond, Nscale delivers the compute foundation for enterprise AI training, fine-tuning, and inference at scale.

‍Media Contact:
[email protected]

Investor Contact:
[email protected]

Logo – https://mma.prnewswire.com/media/2928710/Nscale_Logo.jpg

SOURCE Nscale

PHILADELPHIA, March 6, 2026 — Voomi Supply, a fast-growing B2B eCommerce platform serving the HVAC industry and broader industrial trades, today announced it has closed a $10 million Series A funding round led by Asymmetric Capital Partners.

Voomi Supply fills a gap in the HVAC and industrial supply market by simplifying how businesses discover and procure products across a highly diverse supplier landscape. Voomi Supply gives customers access to over one million HVAC and industrial parts and equipment SKUs. Voomi takes a technology-first approach, built on an AI-powered platform designed to scale with its growing supplier and customer base.

“Voomi Supply was built to modernize purchasing across HVAC and industrial supply markets, delivering simplicity, speed, and competitive pricing for all buyers while unlocking new sales channels for suppliers,” said RJ Cilley, CEO of Voomi Supply. “We’re excited to partner with Asymmetric Capital Partners, whose approach and long-term perspective reflect how we’re building Voomi Supply.”

The investment follows a period of rapid growth for Voomi Supply and positions the company for continued expansion. The new capital will accelerate development of Voomi’s technology platform, expand its supplier network, and drive growth into new product categories, while scaling the team and customer experience.

“Voomi is attacking a massive, fragmented market with a clear vision and strong execution,” said Rob Biederman, Managing Partner at Asymmetric Capital Partners. “The team has scaled the business with a disciplined, capital-efficient approach, prioritizing supplier value and real customer demand. We’re excited to partner with RJ and the Voomi Supply team as they continue to modernize HVAC and industrial distribution.”

Highmount Capital also participated in the round led by David Hawkins.

The Series A builds on the foundation established by founders Faron Schonfeld, Andy Chalofsky, and Josh Chalofsky, together with existing investor Operator Partners.

About Voomi Supply

Voomi Supply is a technology-driven B2B eCommerce platform focused on simplifying procurement for the trades. Serving HVAC, plumbing, electrical, and industrial buyers, Voomi delivers a large digital catalog, competitive pricing, and a streamlined purchasing experience built for professional customers. Voomi Supply was founded by Faron Schonfeld, Andy Chalofsky, and Josh Chalofsky.

About Asymmetric Capital Partners

Founded in 2021, Asymmetric Capital Partners (“Asymmetric”) is an early-stage technology investment firm purpose-built to back founders with conviction, concentration, and real operational support. The firm invests in disruptive technology-driven companies in the Pre-seed through Series A stages. Asymmetric’s DNA is different by design: its team blends rigorous investing experience with hands-on operating expertise, having built, scaled, and acquired companies themselves. This allows Asymmetric to partner with founders as true thought partners — from refining an idea pre-launch to building go-to-market strategies, recruiting key executives, or pursuing acquisitions. With over $240 million in assets under management, Asymmetric has backed nearly 90 companies to date.

Media Contact
[email protected] 

SOURCE Voomi Supply

DALLAS, March 5, 2026 — Yellow Stripes Capital (“YSC”), a private investment firm based in Dublin, Ohio, has acquired a majority stake in NoblQ, a fast‑growing global digital transformation company. The partnership strengthens NoblQ’s position at the forefront of AI‑enabled enterprise modernization and underscores YSC’s commitment to building next‑generation technology platforms.

“We invest in companies that are not just transforming industries but defining how technology enables growth,” said Harsh Acharya, Founder and CEO of Yellow Stripes Capital. “Bala and the NoblQ team have built a global IT services powerhouse. Together, we’ll scale their impact across industries ready for intelligent transformation.”

“This partnership gives NoblQ the fuel to accelerate innovation that directly transforms client outcomes,” said Bala Chandra, CEO of NoblQ. “With YSC’s expertise in operational scale and global expansion, we’re positioned to lead the next chapter of enterprise AI adoption.”

Strategic Partnership Signals New Growth Phase

Through this investment, YSC will collaborate closely with NoblQ’s leadership to advance its AI‑driven transformation strategy, enhance delivery operations across North America, Europe, and Asia, and expand its digital engineering and enterprise modernization practices.

As part of the transaction, Harsh Acharya has been appointed Chairman of NoblQ’s Board of Directors, where he will guide the company’s strategic growth and innovation initiatives alongside the executive team.

Leadership Transition and Legacy

The transaction also marks a meaningful leadership transition for Caldwell Velnambi, founder and former Chairman of NoblQ, and Nepoleon Duraisamy, former Co‑Chairman and Chairman & CEO of its subsidiary, Jeevan Technologies Inc., both of whom have sold their remaining interests in the company.

Under Caldwell’s leadership, NoblQ transformed from an ERP services provider into a diversified global digital transformation partner, executing five strategic acquisitions and building an integrated portfolio spanning consulting, data, and platform modernization. Mr. Velnambi now launches NoblQ Ventures, an independent venture capital firm.

Mr. Duraisamy leaves a legacy of engineering excellence and workforce development, having built strong technology delivery foundations in India and the United States – contributions recognized as instrumental to NoblQ’s success and to the broader technology community. Over the past 25 years, he built Jeevan Technologies into a high‑performing professional services organization defined by advancing innovation, client trust, and operational discipline.

NoblQ and Yellow Stripes Capital extend their sincere appreciation to Caldwell Velnambi and Nepoleon Duraisamy for their visionary leadership, strategic foresight, and enduring contributions to the company’s growth and evolution.

About NoblQ

NoblQ is a global digital transformation and IT services company specializing in AI‑driven engineering, enterprise platforms, and professional services. With more than 1,600 professionals across North America, Europe, and Asia, NoblQ partners with enterprises to modernize mission‑critical systems, harness data and artificial intelligence, and deliver measurable business results. 

Explore NoblQ’s offerings at https://www.noblq.com/solutions/artificial-intelligence

About Yellow Stripes Capital

Yellow Stripes Capital is a private investment firm headquartered in Dublin, Ohio, focused on acquiring and building high‑performing technology and services businesses. The firm combines disciplined capital, operational expertise, and long‑term partnership to unlock value and drive sustainable growth. Learn more about its portfolio and investment philosophy at https://www.yellowstripescapital.com/philosophy. 

SOURCE Nobl Q LLC

SAN FRANCISCO, March 5, 2026 — Novitas Holdings, a technology-focused investment firm founded by former Memora Health CEO Manav Sevak, has officially launched to support founder-led companies across multiple industries. According to Novitas Holdings, the firm combines financial backing with hands-on operational and strategic guidance designed to help startups navigate early-stage growth and long-term expansion. The launch follows Sevak’s exit from Memora Health after the company’s acquisition by Commure.

The acquisition of Memora Health by Commure, a provider of healthcare operating systems, closed in mid-2024. While financial terms were not publicly disclosed, the transaction represented an important milestone for both organizations. Memora’s patient engagement technology is now integrated into Commure’s unified platform, expanding the company’s ability to deliver scalable digital infrastructure for healthcare providers.

According to Novitas Holdings, the firm builds upon the operational experience gained during the growth of Memora Health. Under Manav Sevak’s leadership, Memora developed a platform designed to automate and personalize patient communication for healthcare systems. The company raised more than $80 million in funding from investors including Y Combinator and Andreessen Horowitz and became known for helping clinicians streamline workflows while improving patient outcomes.

Novitas Holdings aims to extend many of those operational principles to the companies it supports. In addition to providing early-stage investment capital, the firm works closely with founders to provide strategic guidance, operational frameworks, and mentorship designed to help startups scale efficiently.

The firm focuses on companies solving meaningful industry challenges and building products intended for long-term relevance. Novitas Holdings notes that its investment strategy may include both early-stage investments and participation in acquisitions of technology businesses, enabling portfolio companies to accelerate development and expand market reach.

Memora Health’s impact on healthcare technology provides important context for the launch of Novitas Holdings. The platform helped healthcare providers automate routine patient interactions such as appointment reminders, intake processes, post-discharge follow-ups, and condition-specific care plans. By reducing administrative burdens, healthcare teams were able to focus more directly on patient care. The platform’s ability to integrate into clinical workflows and improve patient engagement contributed to its growth within the healthcare technology sector.

When Commure acquired Memora Health in 2024, the merger combined two organizations focused on modernizing healthcare infrastructure. Memora’s patient engagement capabilities became part of Commure’s broader healthcare operating system, strengthening the platform’s ability to support hospitals and health systems nationwide.

Novitas Holdings describes its model as a technology-enabled investment platform that applies data-driven insights and operational expertise to portfolio companies. In addition to capital investment, the firm collaborates with founders on product development, go-to-market strategies, talent acquisition, and operational scaling.

Through Novitas Holdings, Sevak is focused on supporting entrepreneurs building durable, mission-driven companies. According to the firm, its investment philosophy centers on long-term value creation and strategic collaboration with founders working to solve complex problems across industries.

As Novitas Holdings begins building its portfolio, the firm and its team of experienced operators aim to support the next generation of technology innovators. With a focus on founder-led businesses and sustainable growth, the organization seeks to partner with startups positioned to create meaningful impact within their industries.

About Novitas Holdings

Novitas Holdings is a technology-focused investment firm that partners with founder-led companies across multiple sectors. Founded by former Memora Health CEO Manav Sevak, the firm combines capital investment with operational expertise, strategic guidance, and mentorship to help startups scale effectively. Novitas Holdings works closely with entrepreneurs on product development, go-to-market execution, talent strategy, and long-term growth initiatives.

Media Contact
Novitas Holdings
Email: [email protected]
LinkedIn: https://www.linkedin.com/in/manavsevak/

SOURCE Novitas Holdings

STEWARTVILLE, Minn., March 5, 2026 — Minnesota Medical Technologies Corporation, a leading innovator in continence care solutions, today announced it has raised $20.6 million of new capital through a Series A preferred equity financing co-led by HM Venture Partners and Southeast Minnesota Capital Partners. The company will use the new capital to fuel the commercial launch of its lead fecal incontinence product in the US market and scale operations to meet growing demand.

“This funding marks a pivotal moment for our company,” said David A. Jonas, CEO of Minnesota Medical Technologies Corporation. “With the support of our investors, we are now positioned to launch StaySure^™ into the newly cleared US market and expand our talented team. For the millions of people living with fecal incontinence, this represents an opportunity to finally access a safe, effective, and life-changing solution.”

The funds from the Series A financing will be used exclusively for:

• U.S. Market Entry: Establish the operation, commercial, and distribution infrastructure needed to successfully launch StaySure^™ across multiple channels in the US market.
• Talent Acquisition: Strategically build a high-performing team across sales, marketing, and customer care to accelerate market penetration, drive market education and brand awareness, and sustainable revenue growth.
• Financial Security – Provide debt reduction and financial security to support disciplined, sustainable growth.

Founded in 2015, Minnesota Medical Technologies Corporation was established to address one of healthcare’s most significant yet underserved conditions: fecal incontinence. In collaboration with Mayo Clinic gastroenterologist Adil Bharucha, MD, the company created a simple, single use device designed to provide an effective alternative to absorbent products that have historically dominated the market.

Fecal incontinence (which is commonly known as “accidental bowel leakage”) affects more than 2% of the global population, representing tens of millions of individuals worldwide, with most relying on adult diapers and pads rather than restorative solutions. This represents a substantial and largely untapped market opportunity for innovative, clinically validated interventions that improve quality of life.

Following the establishment of a world-class medical device manufacturing facility and the successful completion of a clinical trial at Mayo Clinic, the FDA granted clearance for StaySure^™ in July 2025. With regulatory approval secured, Minnesota Medical Technologies is now positioned to scale its commercialization efforts. This Series A fundraise will allow us to accelerate physician and patient education, expand distribution channels, and support broad market penetration of this differentiated solution, unlocking meaningful value in a large, underserved global market. 

About Minnesota Medical Technologies Corporation
Founded and driven by a talented, experienced team with a proven track record of value creation, including leadership experience from Rochester Medical Corporation (sold in 2013 for $262M to CR Bard), Minnesota Medical Technologies Corporation is committed to developing, making, and selling Continence Care Products of unmatched comfort, performance, and quality. The company’s innovative StaySure^™ product is a clinically proven, single use insert designed to safely and effectively manage accidental bowel leakage and fecal incontinence. By offering a discreet, patient-centered alternative to traditional absorbent products and invasive surgeries, StaySure™ represents a differentiated solution in a large and underserved market. With experienced leadership, validated clinical data, and regulatory clearance, the company is strategically positioned to scale commercialization and deliver meaningful impact for patients while generating significant long-term shareholder value. 

About HM Venture Partners
HM Venture Partners is a San Franciso-based venture capital firm that backs high growth medtech and biotech companies globally and across all stages. Founded in 2019 by Robert Luo, HMVP has three funds totaling over $600 million under management. Prior to founding HMVP, Mr. Luo was a senior investment officer in Mayo Clinic Treasury Services.

About Southeast Minnesota Capital Partners
SE MN Capital Partners is a venture capital management company based in Rochester, MN that manages two early-stage venture capital funds that focus on Minnesota medtech companies as well as seven single company special purpose vehicles. David Herbert and Harry Hoffman founded SMCP in 2022 following their retirements from business and investment leadership roles at Mayo Clinic.

Minnesota Medical Technologies Corporation Contact:
David A. Jonas
CEO and President
[email protected]
507-533-0366
www.mnmedicaltechnologies.com
www.staysuretoday.com

SOURCE Minnesota Medical Technologies

Investor Event will Focus on Connecting Capital, Technology and Science to Accelerate Drug Discovery

BOSTON, March 5, 2026 — Cambridge Healthtech Institute today announced the agenda for the third annual Bio-IT World Venture, Innovation & Partnering Conference, an exclusive gathering of more than 200 senior-level investors, corporate executives, entrepreneurs and startups, with a focus on connecting capital, technology, and science to accelerate drug discovery.

The May 19 event in Boston will be part of the 25^th annual Bio-IT World Conference & Expo, the premier global gathering of 2,900 leaders from the biomedical research and IT communities taking place May 19-21. Participants will include leaders from AstraZeneca, Breyer Capital, Eli Lilly and Company, F-Prime Capital, MIT, Obvious Ventures, Sanofi Ventures, SandboxAQ, Science Capital, Soufflé Therapeutics, Third Rock Ventures, T.Rx Capital, and Wellfleet Advisors, among many others.

This year’s event will include Keynote Fireside Chats featuring:

• Mike Nally, Chief Executive Officer, Generate:Biomedicines and CEO-Partner, Flagship Pioneering on Leadership at the Cutting Edge: Innovation, Strategy & Biotech’s Next Frontier. Since 2021, Nally has driven financing rounds exceeding $750 million and positioned Generate:Biomedicines at the forefront of AI-driven drug discovery.
• Michael Chambers, Founding CEO, Aldevron on Engineering Access: Scalable Genomics, Technology & the Future of Medicine, who built one of genomic medicine’s most critical infrastructure companies, leading to a landmark $9.6 billion exit.

“This is a unique opportunity to hear from exceptionally visionary leaders at the forefront of life sciences. These speakers will share their insights on the most compelling opportunities in the market today, while offering a forward-looking perspective on the critical challenges that must be solved to meaningfully advance drug discovery,” said Eileen Murphy, Conference Producer.

Other session topics will include Funding the Modern Pipeline: Capital Strategy Across Biology, Technology, and Informatics; The Future of Lab Funding: Building Stronger Pathways Between Academia, Capital, and Spinouts; The New Rules of VC, Pharma, and Industry Leader Collaboration; and more.

Participants in the investor conference will be able to take advantage of two more days of in-depth education and networking at the Bio-IT World Conference & Expo, featuring more than 200 presentations on the advanced technologies driving progress in biomedical research, drug discovery, and clinical care.

The larger event will open at 4:30 p.m. on May 19 with a keynote presentation on Research, Funding and Advocacy for Rare Diseases, followed by a welcome reception in the Exhibit Hall, where 150 organizations will showcase their cutting-edge technologies and solutions.

To register for the Bio-IT World investor conference and the Bio-IT World Conference & Expo, please click this link. Those who register by March 6 will enjoy a discounted rate. Media who would like a press pass should click here.

About Cambridge VIP
Cambridge VIP – Venture, Innovation & Partnering conferences unite senior-level investors, corporate executives, entrepreneurs, and startup leaders from diverse sectors. These exclusive gatherings feature engaging industry panels and fireside chats, fostering meaningful networking and interactions. Join us at these innovative conferences to gain strategic insights, candid perspectives, and valuable business recommendations in your area of interest. Discover who’s investing, track funding activities, and witness the commercialization of emerging technologies solving real-world challenges.

About Bio-IT World Conference & Expo
Cambridge Healthtech Institute’s Bio-IT World Conference & Expo is the world’s premier event showcasing technologies and analytic approaches that solve problems, accelerate science, and drive the future of precision medicine. Bio-IT World unites a global community of experts in life sciences, pharmaceuticals, clinical research, healthcare, informatics, and IT, all dedicated to advancing biomedical research, drug discovery and development, and healthcare innovations.

SOURCE Bio-IT World Conference & Expo

Round led by Harbert Growth Partners with participation from Northwestern Mutual Future Ventures and Bull City Venture Partners

RALEIGH, N.C., March 5, 2026 — Levitate, the AI-powered relationship marketing platform serving more than 8,000 businesses, today announced it has raised $16 million in a new funding round, bringing its total capital raised to $71 million.

The round was led by Harbert Growth Partners, with participation from Bull City Venture Partners and Northwestern Mutual Future Ventures.

Levitate was founded in 2017 with the belief that AI could help relationship-based businesses scale meaningful, personal communication without losing what makes it effective: the human connection. Today, Levitate’s platform helps businesses stay top of mind with clients and prospects through consistent outreach, smarter targeting, and automation that still feels personal.

The new investment will accelerate Levitate’s AI innovation roadmap, including both internal AI capabilities and customer-facing tools that make it easier for small businesses to execute high-quality relationship marketing at scale. Levitate will also continue to expand its Service-as-Software model, combining intelligent automation with hands-on strategy to help customers drive measurable outcomes.

“Our original thesis was simple: AI should help relationship-based businesses become more consistent, more thoughtful, and more scalable in how they show up for their clients,” said Jesse Lipson, Founder and CEO of Levitate. “This investment allows us to build more tools that make AI practical and accessible for small businesses, while continuing to strengthen the Service-as-Software experience our customers rely on.”

The company plans to use the funding not only to advance its AI innovation roadmap, but to expand its customer success and sales teams across the United States and Canada, and grow its market reach to serve a broader range of relationship-focused small businesses.

About Levitate

Founded in 2017, Levitate is more than just a software platform – it’s a catalyst for building authentic relationships. Levitate’s Happiness Platform equips relationship-based businesses with the tools and coaching to cultivate meaningful interactions with clients, donors, referral sources, and prospects. Levitate allows customers to send tailored emails at scale, post to social media, keep in touch with clients via text, send surveys & event invitations, generate & manage reviews, schedule meetings, send handwritten cards, remember key facts about their contacts, manage their website and blog, and more. For more information about Levitate, visit levitate.ai.

SOURCE Levitate

Funding to reduce caregiver burden at scale through AI-powered, connected senior living solutions

NEW YORK, March 5, 2026 — Sage, the first integrated Care Platform built for senior living and skilled nursing, today announced it has raised a $65 million Series C equity round led by Growth Equity at Goldman Sachs Alternatives with participation from existing investors IVP and Goldcrest. The investment will accelerate Sage’s mission to improve the quality of life for older adults and their caregivers.

By replacing the fragmented, reactive infrastructure of senior care with an AI-powered platform, Sage is shifting the industry from response to prevention — of the falls, declines, and avoidable hospitalizations that too often define it. Alongside the funding, Sage announced that it will host its inaugural Caregiver Summit in New York City in fall 2026 as part of its commitment to invest in the workforce it serves.

“Today, more than 40% of U.S. healthcare spending goes toward people over 65, with care needs becoming increasingly complex and ultimately pushing the caregiving workforce to a breaking point. We cannot solve the country’s caregiving crisis with staffing alone. Every caregiver I talk to says the same thing: current tools are not built for how care actually works, contributing to chaotic environments that fail both caregivers and residents,” said Raj Mehra, co-founder and CEO of Sage. “This investment allows us to put caregivers at the center of innovation — by delivering a platform that provides real-time intelligence, and by convening an inaugural summit to ensure their voices and expertise drive the future of the industry.”

The investment comes at an inflection point for America’s most vulnerable population. Today, care teams juggle paper logs, pagers, and outdated systems that tell them nothing until something has already gone wrong: a resident has fallen, a condition has deteriorated, an ambulance has been called. According to S&P Global, one in five Americans, or 72 million people, will be of retirement age by 2030. The caregiving workforce is nowhere near ready: the industry is short 1.8 million licensed caregivers, and those already on the job are leaving at an industry-wide turnover rate of 79%. Sage understands that labor alone will not fix this crisis. By arming caregivers with real-time intelligence and intuitive workflows, Sage empowers them to intervene before a preventable moment becomes a heartbreaking one.

The funding will accelerate Sage’s platform across three areas:

• Predictive AI for Resident Safety: Today, caregivers often discover safety issues after they happen, when intervention is no longer possible. Sage will evolve its AI-driven, industry-leading detection capabilities into a predictive engine that analyzes daily activity patterns, including sleep changes, nighttime wandering, bathroom frequency, and other fall-risk signals, to identify high-risk residents before an adverse event occurs and give caregivers the lead time to step in.
• Unified Caregiver Workflow: Caregivers in most communities toggle between multiple disconnected systems to piece together a resident’s status. This time-consuming process increases cognitive load and delays care. Sage is centralizing data from leading Electronic Health Records, including ALIS, August Health, ECP, PointClickCare and Yardi, into a single real-time care view that surfaces alerts, risk signals, and resident-specific context at the point of care.
• Deeper Investment in Skilled Nursing: Skilled nursing facilities operate under some of the most demanding clinical and regulatory conditions in healthcare, caring for residents with the most acute needs — yet their technology has not kept pace. Sage will deepen its platform’s capabilities for these environments, where integrated infrastructure, predictive intelligence, and streamlined workflows can have the most immediate impact on both caregiver experience and resident outcomes.

“We are experiencing a structural shift in the senior care market, necessitating a complete modernization of its underlying technology,” said Antoine Munfa, Managing Director within Growth Equity at Goldman Sachs Alternatives. “By shifting the industry from a reactive to a proactive model, Sage is creating the scalable infrastructure to help meet the historic demand of an aging population,” said Ryan Leary, Vice President within Growth Equity at Goldman Sachs Alternatives.

In fall 2026, Sage will host its inaugural Caregiver Summit, bringing together frontline caregivers, senior living operators, and industry leaders for a conversation about the future of the profession. The event will feature keynote speakers, hands-on professional development, and continuing education, with the core purpose of giving caregivers — the people who show up every day for America’s older adults — a seat at the table in shaping the tools and policies that govern their work.

The $65 million Series C brings Sage’s total capital raised to $124 million. The new funding comes as Sage grows its platform with Sage Detect, an AI-powered, privacy-conscious monitoring system, and expanded EHR partnerships that extend the company’s footprint nationwide.

About Sage

Sage is the industry’s first fully integrated care platform for senior living and skilled nursing, built by founders who have watched family members navigate a broken care system firsthand. Sage replaces outdated infrastructure with modern software and AI-powered insights, so that aging is defined by dignity, visibility, and truly human care. Sage-powered communities have identified a $275 increase in NOI per resident per month, 50% reduction in falls and 50% faster response times compared to the industry.

About Growth Equity at Goldman Sachs Alternatives
Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $625 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives, including private equity, growth equity, private credit, real estate, infrastructure, sustainability, and hedge funds. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs.

The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets.

The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world’s leading institutions, financial advisors, and individuals. Goldman Sachs has approximately $3.6 trillion in assets under supervision globally as of December 31, 2025.

Since 2003, Growth Equity at Goldman Sachs Alternatives has invested over $13 billion in companies led by visionary founders and CEOs. The team focuses on investments in growth-stage and technology-driven companies spanning multiple industries, including enterprise technology, financial technology, consumer and healthcare.

SOURCE Sage

FAYETTEVILLE, Ark., March 5, 2026 — HTA and Venture Atlas Labs announced a new commercial and clinical acceleration program that connects international health technology companies with leading U.S. clinical partners, evidence-generation opportunities, and strategic market entry pathways. Applications for its inaugural Rural Health Program will open soon.

HealthTech Bridge combines clinical engagement with practical commercialization guidance to help emerging healthtech companies successfully navigate the complex U.S. healthcare landscape. Unlike traditional accelerators, HealthTech Bridge is built specifically for the needs of international scaleups, offering structured clinical validation opportunities, including pilot studies and real-world clinical evaluations with provider partners, alongside commercialization strategy, reimbursement planning, investor readiness, and go-to-market support.

“For international healthtech companies, entering the U.S. market isn’t just about scaling what already works. It requires rethinking commercialization from the ground up. The U.S. healthcare system is complex, opaque, and often unforgiving to business models designed elsewhere,” said Elizabeth Jennings, Managing Partner of Venture Atlas Labs. “Through HealthTech Bridge, we’re helping founders pressure-test their strategy in real time, so they can enter the market with confidence and clarity.”

“Clinical evidence is a linchpin for success in healthcare innovation,” said Jeff Stinson, Director of HTA. “HealthTech Bridge is designed to help international founders not just understand the U.S. market, but generate the clinical proof and provider partnerships that accelerate adoption, reimbursement, and investor confidence.”

HealthTech Bridge builds on HTA’s nearly decade-long track record of facilitating real-world clinical partnerships and research collaborations. HTA’s accelerator ecosystem, including its flagship HeartX program, has historically guaranteed clinical pilots and studies for participants by working directly with hospitals and health systems that choose and sponsor cohort companies.

The first cohort launching through HealthTech Bridge — the Rural Health Program — will soon begin accepting applications. This program will connect innovations that focus on improving cardiometabolic health with rural healthcare providers, community partners, and clinicians working to close gaps in access, outcomes, and care delivery for underserved populations. Rural communities face particularly stubborn challenges, including workforce shortages, infrastructure limitations, and limited access to care.

The Rural Health Program aims to facilitate clinical evaluations and pilot implementations in rural settings, enabling companies to generate evidence in environments where healthtech solutions can make a measurable difference. Participating organizations will gain early access to real-world data and feedback that can inform product development, deployment strategies, and future commercial relationships.

HealthTech Bridge is tailored for startups and scaleups that have demonstrated traction outside the United States but need support with the clinical, regulatory, and commercial complexities of the U.S. healthcare market. The program offers a structured international-focused curriculum, mentorship from proven health care leaders, facilitated clinical studies with U.S. provider organizations, and introductions to investors. Learn more at healthtechbridge.com.

ABOUT HTA
HTA helps drive innovation for healthcare provider organizations through its accelerator programs and internal innovation initiatives. Its flagship accelerator, HeartX, recruits from around the world to support the most accomplished cardiovascular-focused startups in digital health, medical devices, and diagnostic platforms. Companies accepted into the program are guaranteed at least one pilot project or clinical trial with one of the ten largest hospitals and health systems in Arkansas. More information is available at HTA.health.

ABOUT VENTURE ATLAS LABS
Venture Atlas Labs helps international healthcare innovators scale into the U.S. and throughout Europe. By partnering with innovation hubs and investors around the world, Venture Atlas Labs guides commercialization via health economics in 28 countries, regulatory and quality risk structuring, and strategic advice. Their healthcare commercialization workshops are incorporated into clusters, accelerators, and conference programming throughout Europe. Learn more at ventureatlaslabs.com.

For more information, contact:

Jeff Stinson
+1.501.766.0633
[email protected]

Elizabeth Jennings
[email protected]

SOURCE HealthTech Bridge